Anavex Life Sciences gains regulatory clearance to begin U.S. clinical testing of blarcamesine for Fragile X syndrome, expanding its active development programs across three neurological indications.

UC Davis MIND Institute researchers Randi and Paul Hagerman are calling for increased awareness and screening for fragile X-associated conditions. In a new paper published in the New England Journal ...

Numerous potential treatments for neurological conditions, including autism spectrum disorders, have worked well in lab mice but then disappointed in humans. What would help is a noninvasive, ...